Design, synthesis, and biological evaluation of new 2-(4-(methylsulfonyl)phenyl)-N-phenylimidazo[1,2-a]pyridin-3-amine as selective COX-2 inhibitors
Authors:
- 2 March 2023
- journal article
- research article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 32 (5) , 856-868
Abstract
Cyclooxygenase (COX), which plays a role in converting arachidonic acid to inflammatory mediators, could be inhibited by non-steroidal anti-inflammatory drugs (NSAIDs). Although potent NSAIDs are available for the treatment of pain, fever, and inflammation, some side effects, such as gastrointestinal ulcers, limit the use of these medications. In recent years, selective COX-2 inhibitors with a lower incidence of adverse effects attained an important position in medicinal chemistry. In order to introduce some new potent COX-2 inhibitors, a new series of 2-(4-(methylsulfonyl)phenyl)-N-phenylimidazo[1,2-a]pyridin-3-amines was designed, synthesized, and evaluated. The docking studies performed by AutoDock Vina demonstrated that docked molecules were positioned as well as a crystallographic ligand in the COX-2 active site, and SO2Me pharmacophore was inserted into the secondary pocket of COX-2 and formed hydrogen bonds with the active site. The designed compounds were synthesized through two-step reactions. In the first step, different 1-(4-(methylsulfonyl)phenyl)-2-(phenylamino)ethan-1-one derivatives were obtained by the reaction of aniline derivatives and α-bromo-4-(methylsulfonyl)acetophenone. Then, condensation of intermediates with different 2-aminopyridines gave final compounds. Enzyme inhibition assay and formalin test were performed to evaluate the activity of these compounds. Among these compounds, 8-methyl-2-(4-(methylsulfonyl)phenyl)-N-(p-tolyl)imidazo[1,2-a]pyridin-3-amine (5n) exhibited the highest potency (IC50 = 0.07 µM) and selectivity (selectivity index = 508.6) against COX-2 enzyme (selectivity index: COX-1 IC50/COX-2 IC50). The antinociceptive activity assessment via the formalin test showed that nine derivatives (5a, 5d, 5h, 5i, 5k, 5q, 5r, 5s, and 5t) possessed significant activity compared with the control group with a p value less than 0.05. Graphical AbstractKeywords
All Related Versions
This publication has 46 references indexed in Scilit:
- Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzymeEuropean Journal of Medicinal Chemistry, 2012
- Design and Synthesis of New 1,3‐Benzdiazinan‐4‐one Derivatives as Selective Cyclooxygenase (COX‐2) InhibitorsArchiv der Pharmazie, 2011
- Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitorsEuropean Journal of Medicinal Chemistry, 2010
- Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitorsBioorganic & Medicinal Chemistry, 2010
- Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitorsBioorganic & Medicinal Chemistry, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analoguesBioorganic & Medicinal Chemistry Letters, 2008
- Cyclooxygenase inhibitors – current status and future prospectsEuropean Journal of Medicinal Chemistry, 2001
- Prostaglandin synthase 2Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and catsPain, 1977